Purpose This phase III study compared the safety and efficacy of the following three different
irinotecan-containing regimens in the first-line treatment of metastatic colorectal cancer …

Purpose: Randomized trials in fluorouracil (FU)-refractory colorectal cancer demonstrate
significant survival advantages for patients receiving irinotecan. We prospectively compared …

Background The study aimed to demonstrate the noninferiority of capecitabine to 5-
fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first …

Background Irinotecan is active against colorectal cancer in patients whose disease is
refractory to fluorouracil. We investigated the efficacy of these two agents combined for first …

Background. Irinotecan is a topoisomerase I inhibitor that prolongs survival in patients with
colorectal cancer refractory to fluorouracil (5-FU) and leucovorin (LV). This demonstrated …

Purpose Previously, we reported results of Intergroup N9741, which compared standard
bolus fluorouracil (FU), leucovorin, plus irinotecan (IFL) with infused FU, leucovorin, plus …

Purpose Bevacizumab, a monoclonal antibody against vascular endothelial growth factor,
increases survival when combined with irinotecan-based chemotherapy in first-line …

Background Combination therapy with oral fluoropyrimidine and irinotecan has not yet been
established as first-line treatment of metastatic colorectal cancer (mCRC). We carried out a …

PURPOSE: To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination
with oxaliplatin (l-OHP) plus fluorouracil (5-FU)/leucovorin (LV)(de Gramont regimen) as first …

Background The combination of fluorouracil and leucovorin has until recently been standard
therapy for metastatic colorectal cancer. Irinotecan prolongs survival in patients with …